Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed.

The accumulated balance of the retained fees has now been reinvested as disclosed below.

Going forward, notional ADSs of the Company will be allocated on a quarterly basis.

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.

GSK - GlaxoSmithKline plc published this content on 26 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 July 2017 11:50:07 UTC.

Original documenthttp://otp.investis.com/clients/uk/GlaxoSmithKline2/rns_new/regulatory-story.aspx?cid=410&newsid=895639

Public permalinkhttp://www.publicnow.com/view/6C45E13D10879C2BB339A8C18998103364598266